Biomarker for diagnosing hemorrhagic smog disease and application thereof
By using WNT4 as a biomarker for hemorrhagic moyamoya disease, and detecting WNT4 levels in human brain vascular smooth muscle cells, a diagnostic kit for hemorrhagic moyamoya disease was developed. This solves the problem of diagnostic lag in existing technologies, enabling early diagnosis and treatment, and reducing the risk of stroke.
Patent Information
- Application Number
- CN202410997924.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-12
AI Technical Summary
Current technologies lack accurate biomarkers for diagnosing hemorrhagic moyamoya disease, leading to diagnostic delays, difficulty in early detection and treatment, and an increased risk of stroke.
Using WNT4 as a biomarker for hemorrhagic moyamoya disease, we developed a diagnostic reagent or kit for hemorrhagic moyamoya disease by detecting the level of WNT4 in human brain vascular smooth muscle cells, and then used ELISA and Western Blot methods for detection.
It provides the possibility of early diagnosis of hemorrhagic moyamoya disease, reduces the risk of stroke, and improves the timeliness and accuracy of treatment.
Smart Images

Figure CN118937685A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of molecular diagnosis, and in particular to a biomarker for diagnosing hemorrhagic moyamoya disease and application thereof. Background Art
[0002] Moyamoya Disease (MMD) is caused by chronic progressive stenosis of the bilateral internal carotid artery terminals, which causes compensatory development of collateral vessels at the base of the brain, leading to the formation of an abnormal vascular network at the base of the brain. Because the vascular network looks like a cloud of smoke in cerebral angiography (DSA), it is named "Moyamoya Disease". MMD can also cause severe cognitive dysfunction, epileptic seizures and other symptoms, severely reducing the quality of life of patients and bringing huge economic and mental burdens to families and society.
[0003] The main classification method of moyamoya disease is to divide it into ischemic moyamoya disease and hemorrhagic moyamoya disease according to the first symptom. Because moyamoya disease often starts with stenosis or occlusion of the terminal internal carotid artery, ischemia is the basic symptom. However, the abnormally proliferating vascular network caused by vascular occlusion does not have the complete structure of normal blood vessels, and most of them are fragile pathological blood vessels, which becomes the basis for the occurrence of hemorrhagic stroke. Therefore, due to the characteristics of the pathological structure, patients with moyamoya disease are actually facing the dual risks of cerebral ischemia and cerebral hemorrhage. In terms of treatment, moyamoya disease lacks specific drugs for the pathogenesis, and anticoagulants are very few drugs that can achieve long-term benefits for patients with moyamoya disease, but this may be a contraindication for patients with hemorrhagic moyamoya disease. In addition, revascularization surgery, as the only treatment procedure for moyamoya disease, also presents different risks and prognosis in the ischemic and hemorrhagic moyamoya disease patient groups.
[0004] Therefore, the differentiation of moyamoya disease subtypes is crucial for the treatment and life management of patients. However, the current diagnosis of moyamoya disease still mainly relies on whole brain angiography and clinical experience, lacking accurate biomarkers and detection indicators. In addition, the classification based on the first symptom has a certain lag in diagnosis and treatment, making it difficult to achieve "early detection, early diagnosis, and early treatment". The treatment selection and prognosis of stroke caused by moyamoya disease are very time-dependent. Therefore, there is an urgent need for the emergence of a biomarker for hemorrhagic moyamoya disease. Summary of the invention
[0005] The purpose of the present invention is to provide a biomarker for diagnosing hemorrhagic moyamoya disease and its application.
[0006] In one aspect, the present invention provides a biomarker for diagnosing hemorrhagic moyamoya disease, wherein the biomarker is WNT4 (Wingless-type MMTV integration site family member 4).
[0007] In one embodiment, the amino acid sequence of the biomarker is shown as SEQ ID No.1.
[0008] In one embodiment, the CDS sequence of the biomarker is shown as SEQ ID No.2.
[0009] On the other hand, the present invention provides use of the biomarker in preparing a detection reagent or a detection kit for hemorrhagic moyamoya disease.
[0010] On the other hand, the present invention provides use of a reagent for detecting the biomarker in a biological sample in preparing a detection reagent or a detection kit for hemorrhagic moyamoya disease.
[0011] In one embodiment, the biological sample is derived from the blood or serum of the subject to be tested.
[0012] In one embodiment, the biological sample is obtained by the following steps:
[0013] (1) Human cerebral vascular smooth muscle cells were incubated in a cell culture medium containing 2% FBS for 24 hours;
[0014] (2) stimulating the human brain vascular smooth muscle cells obtained in step (1) with a serum stimulation medium, wherein the serum stimulation medium contains 2.5% heat-inactivated serum of the subject to be tested;
[0015] (3) The biological sample is derived from human cerebral vascular smooth muscle cells or a culture / extract thereof obtained in step (2).
[0016] In one embodiment, the serum is heat inactivated at a temperature of 50°C and the inactivation time is 20 min.
[0017] In one embodiment, the serum stimulation medium is a DMEM medium containing 2.5% heat-inactivated serum of the subject to be tested.
[0018] In one embodiment, the cell culture medium for culturing the human brain vascular smooth muscle cells is a smooth muscle cell culture medium containing 2% FBS.
[0019] In one embodiment, the cell culture medium for culturing the human brain vascular smooth muscle cells is a smooth muscle cell culture medium containing 1% P / S dual antibody, 1% smooth muscle cell growth supplement (SMCGS) and 2% FBS.
[0020] In one embodiment, the reagents include reagents for detecting the biomarker at the protein level.
[0021] In one embodiment, the method for detecting the biomarker in a biological sample comprises ELISA and / or Western Blot.
[0022] In one embodiment, the amount or concentration of the biomarker in the biological sample is significantly increased.
[0023] In one embodiment, the amount or concentration of the biomarker in the biological sample is significantly increased compared to a biological sample from a normal person.
[0024] On the other hand, the present invention provides a detection reagent or a detection kit for hemorrhagic moyamoya disease, wherein the detection reagent or the detection kit comprises a reagent for detecting the biomarker in a biological sample.
[0025] On the other hand, the present invention provides the use of the biomarker as a target in the preparation of a drug for treating hemorrhagic moyamoya disease.
[0026] In another aspect, the present invention provides a method for screening a drug having a therapeutic effect on hemorrhagic moyamoya disease, the method comprising the following steps:
[0027] (1) detecting the level of the biomarker in the blood or serum of a patient with hemorrhagic moyamoya disease;
[0028] (2) administering the test drug to the subject;
[0029] (3) detecting the level of the biomarker in the blood or serum of the patient with hemorrhagic moyamoya disease after administration;
[0030] (4) comparing the biomarker levels obtained in step (1) and (3); if the biomarker level obtained in step (1) is higher than the biomarker level obtained in step (3), determining that the drug to be tested is a drug having a therapeutic effect on hemorrhagic moyamoya disease.
[0031] Beneficial Effects
[0032] The present invention provides a biomarker WNT4 for diagnosing hemorrhagic moyamoya disease. Detecting the level of the biomarker can provide a basis for diagnosing hemorrhagic moyamoya disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 .WNT4 levels in serum of patients with hemorrhagic MMD, patients with ischemic MMD and healthy subjects.
[0034] Figure 2 .WNT4 levels in HBVSMCs stimulated with serum from patients with hemorrhagic MMD, patients with ischemic MMD, and healthy subjects.
[0035] Figure 3 . Transfection efficiency of HBVSMC cells.
[0036] Figure 4 .Effects of overexpression of WNT4 on cell apoptosis and migration.
[0037] Figure 5 .Effects of overexpression of WNT4 on cytokines. DETAILED DESCRIPTION
[0038] The present invention is further described below in conjunction with the embodiments. The following description is only a preferred embodiment of the present invention, and does not limit the present invention in other forms. Any technician familiar with the profession may use the above disclosed technical content to change it into an equivalent embodiment with equivalent changes. Any simple modification or equivalent change made to the following embodiments based on the technical essence of the present invention without departing from the content of the present invention falls within the protection scope of the present invention.
[0039] Example 1. WNT4 levels in patients with hemorrhagic moyamoya disease, patients with ischemic moyamoya disease and healthy subjects
[0040] 1. Extraction of serum from patients with moyamoya disease
[0041] 1.1 Obtaining peripheral blood from patients with moyamoya disease: 8 ml of peripheral venous blood was collected from patients with moyamoya disease (30 patients with hemorrhagic moyamoya disease, 30 patients with ischemic moyamoya disease and 20 healthy subjects as controls) in CPT anticoagulant tubes (Becton Dickinson, Basel, Switzerland) and stored at 37°C to maintain cell activity.
[0042] 1.2 Obtain serum from patients with moyamoya disease: Place the blood collection tube in a centrifuge and balance it; centrifuge at 3000 rpm, 4°C for 10 min; aspirate the upper layer of serum and place it in a 2 ml cryotube.
[0043] 1.3 Storage of Moyamoya disease serum: Store the cryopreserved tubes in a -80℃ refrigerator for future use.
[0044] 2. ELISA detection of WNT4 in serum of patients with moyamoya disease
[0045] Prepare the standard according to the reagent instructions. The concentrations of TNF-α standard are: 1500, 750, 375, 187.5, 94, 47, 23.5, 0pg / mL. Refer to the analysis layout table to determine the number of wells to be used, and return the remaining wells and desiccant to the bag and seal it. Store the unused wells at 4°C. Add 100μL of standard and sample to each well. Cover with the provided adhesive strip. Incubate at 37°C for 2 hours. Remove the liquid from each well without washing. Add 100μL of biotin antibody (1x) to each well. Cover with a new adhesive strip. Incubate at 37°C for 1 hour. Aspirate each well and wash, repeat this process twice, for a total of three washes. Add 100μL of enzyme-labeled avidin (1x) to each well. Cover the microtiter plate with a new adhesive strip. Incubate at 37°C for 1 hour. Repeat the aspiration / washing process 5 times. Add 90μL TMB substrate to each well. Incubate at 37°C for 15-30 minutes, protected from light. Add 50 μL of stop solution to each well to terminate the reaction, and immediately measure the optical density (OD value) of each well at a wavelength of 450 nm using an ELISA reader.
[0046] WNT4 is the abbreviation of Wingless-type MMTV integration site family member 4, and its amino acid sequence is shown in SEQ ID No.1, and its CDS sequence is shown in SEQ ID No.2. It belongs to the WNT family member on chromosome 1p36. It can participate in the regulation of various important cell functions in cells, such as cell proliferation, apoptosis, migration, etc., through the WNT / β-catenin classical pathway.
[0047] Amino acid sequence of WNT4 (SEQ ID No. 1):
[0048] msprsclrsl rllvfavfsa aasnwlylak lssvgsisee etceklkgli qrqvqmckrnlevmdsvrrg
[0049] aqlaieecqy qfrnrrwncs tldslpvfgk vvtqgtreaa fvyaissagv afavtracssgelekcgcdr
[0050] tvhgvspqgf qwsgcsdnia ygvafsqsfv dvrerskgas ssralmnlhn neagrkailthmrveckchg
[0051] vsgscevktc wravppfrqv ghalkekfdg ateveprrvg ssralvprna qfkphtdedlvylepspdfceqdmrsgvlg trgrtcnkts kaidgcellc cgrgfhtaqv elaercsckf hwccfvkcrqcqrlvelhtc r。
[0052] CDS sequence of WNT4 (SEQ ID No.1):
[0053] Atgagtccccgctcgtgcctgcgttcgctgcgcctcctcgtcttcgccgtcttctcagccgccgcgagcaactggctgta
[0054] cctggccaagctgtcgtcggtggggagcatctcagaggaggagacgtgcgagaaactcaagggcctgatccagagg
[0055] caggtgcagatgtgcaagcggaacctggaagtcatggactcggtgcgccgcggtgcccagctggccattgaggagtg
[0056] ccagtaccagttccggaaccggcgctggaactgctccacactcgactccttgcccgtcttcggcaaggtggtgacgcaa
[0057] gggactcgggaggcggccttcgtgtacgccatctcttcggcaggtgtggcctttgcagtgacgcgggcgtgcagcagt
[0058] ggggagctggagaagtgcggctgtgacaggacagtgcatggggtcagcccacagggcttccagtggtcaggatgct
[0059] ctgacaacatcgcctacggtgtggccttctcacagtcgtttgtggatgtgcgggagagaagcaagggggcctcgtccag
[0060] cagagccctcatgaacctccacaacaatgaggccggcaggaaggccatcctgacacacatgcgggtggaatgcaagt
[0061] gccacggggtgtcaggctcctgtgaggtaaagacgtgctggcgagccgtgccgcccttccgccaggtgggtcacgca
[0062] ctgaaggagaagtttgatggtgccactgaggtggagccacgccgcgtgggctcctccagggcactggtgccacgcaa
[0063] cgcacagttcaagccgcacacagatgaggacctggtgtacttggagcctagccccgacttctgtgagcaggacatgcg
[0064] cagcggcgtgctgggcacgaggggccgcacatgcaacaagacgtccaaggccatcgacggctgtgagctgctgtgc
[0065] tgtggccgcggcttccacacggcgcaggtggagctggctgaacgctgcagctgcaaattccactggtgctgcttcgtcaagtgccggcagtgccagcggctcgtggagttgcacacgtgccgatga.
[0066] The results are as follows Figure 1 As shown, the WNT4 content in the serum of normal people is the lowest; the WNT4 content in the serum of patients with ischemic moyamoya disease is slightly higher than that of normal people; the WNT4 content in the serum of patients with hemorrhagic moyamoya disease is the highest, significantly higher than that of normal people and patients with ischemic moyamoya disease. Figure 1 In the figure, the HC group is the WNT4 concentration in the serum of normal people, the IS group is the WNT4 concentration in the serum of patients with ischemic moyamoya disease, and the HEM group is the WNT4 concentration in the serum of patients with hemorrhagic moyamoya disease.
[0067] 3. WNT4 detection in individualized cell models of patients with moyamoya disease
[0068] 3.1. Subculture and serum stimulation of human brain vascular smooth muscle cells (HBVSMC)
[0069] The culture conditions of human brain vascular smooth muscle cells are smooth muscle cell culture medium (SMCM culture medium) containing 1% P / S double antibody, 1% smooth muscle cell growth supplement (SMCGS) and 2% FBS. When the cells are fused to 90%, the old culture medium is discarded, and the cells are washed twice with 2mL PBS. After discarding PBS, 2mL 0.25% trypsin-0.02% EDTA mixed digestion solution is added and observed under a microscope for about 30s. When the cells become round, 2mL culture medium is quickly added to terminate digestion, and the cells are gently blown and collected. 800rpm, 4℃, centrifuged for 5min, the supernatant is discarded, the cells are resuspended with culture medium, cultured in bottles, and the medium is changed every other day. After human brain vascular smooth muscle cells are incubated with smooth muscle cell culture medium containing 2% FBS for 24 hours, DMEM culture medium containing 2.5% heat-inactivated serum from patients with moyamoya disease is replaced and incubated for another 24 hours for serum stimulation. The condition for heat inactivation is to put the serum bottle into a 50℃ water bath for 20min.
[0070] 3.2 Western Blot Detection of WNT4
[0071] According to the experimental grouping, 1 mL of RIPA with PMSF was added to each 100 μL compressed volume of cell sample. After full lysis, centrifuge at 12000g for 5 min at 4°C, and immediately aspirate the supernatant into a pre-cooled Eppendorf tube, which is the extracted cell protein, and freeze it at -80°C for later use. Protein quantification was performed by BCA method, and finally 5× loading buffer was added in boiling water bath for 10 min. The sample preparation was completed and can be stored at -20°C.
[0072] According to the different molecular weights of the proteins to be tested, 10% separation gel and 5% concentration gel were prepared and SDS-PAGE gel was cast. The composition is shown in Table 1 and Table 2:
[0073] Table 1. SDS-PAGE electrophoresis separation gel ratio table
[0074]
[0075] Add 5 mL of prepared separation gel to each gel plate, then add isopropanol to press the gel. After the gel line is formed (gel is complete), place the gel rack horizontally and remove the isopropanol with filter paper.
[0076] Table 2. SDS-PAGE electrophoresis gel ratio
[0077]
[0078] After the concentrated gel is prepared and mixed, inject 2 mL of the prepared concentrated gel into the upper end of the separation gel, and immediately insert the comb vertically, keeping the comb horizontal when inserting it. After the concentrated gel solidifies, remove the comb and place it in the electrophoresis tank with electrophoresis solution.
[0079] After adding an appropriate amount of pre-cooled 1× electrophoresis buffer, start loading (add 5μL Marker and sample to the comb hole from left to right in turn), and adjust the sample loading volume to 60μg. Perform 80V constant voltage electrophoresis for about 30 minutes. After the sample enters the separation gel, adjust the voltage to 120V and continue electrophoresis. When the target band reaches the appropriate position (refer to the position of the pre-stained protein Maker), end the electrophoresis. Cut the PVDF membrane according to the gel size, activate it in methanol for 1 minute, and then soak it in the transfer buffer. The filter paper is also soaked in the transfer buffer for 15 minutes. Make a transfer "sandwich" according to the principle of PVDF membrane ≥ gel ≥ filter paper, and make sure to remove bubbles before starting constant pressure transfer. After the transfer is completed, stain the membrane with Ponceau S dye solution, then wash it twice with TBST, and observe the protein on the membrane.
[0080] After soaking the membrane with TBS from bottom to top, move it to a plate containing blocking solution (5% skim milk powder TBST solution) and shake it on a decolorizing shaker at room temperature for 1 hour to block the immunoglobulin binding sites of the PVDF membrane. Wash the residual liquid on the membrane with TBST, then place the membrane in a ziplock bag with a sealer, seal the three sides, add the primary antibody diluted to an appropriate concentration with TBST (see Table 3 for specific primary antibodies and dilution ratios), remove bubbles as much as possible, seal the bag, and incubate at 4°C overnight. Cut the ziplock bag and wash the membrane 3 times with TBST, 10 minutes each time. Then place the membrane in a closed bag, add an appropriate amount of secondary antibody at an appropriate concentration (see Table 3 for specific secondary antibodies and dilution ratios), seal the bag, and incubate at room temperature for 1 hour. Cut the ziplock bag and wash the membrane 3 times with TBST, 10 minutes each time. Mix equal volumes of chemiluminescent reagent A solution and B solution, and place the membrane protein side down in full contact with the mixture; after 5 minutes, detect it using the Tanon 6600 luminescence imaging workstation. When the same PVDF membrane needs to be exposed multiple times, use strip solution (protein blot membrane regeneration solution) to wash at room temperature for 45 minutes, then wash it 3 times with TBST, and then start again from the blocking step. The subsequent steps are the same as before; the protein expression amount is analyzed by the optical density value using Image Pro Plus 6.0 software, and the relative protein expression amount is calculated as the gray value of the target protein / the gray value of the internal reference protein, and the gray value of the phosphorylated protein / the gray value of the total protein.
[0081] Table 3: Antibodies and dilution concentrations
[0082] Antibody Dilution concentration Wnt4 1:500(WB) GAPDH 1:1000(WB) Rabbit Anti-Mouse IgG H&L(HRP) 1:10000(WB) Goat Anti-Rabbit IgG H&L(HRP) 1:10000(WB)
[0083] The results are as follows Figure 2 As shown, the WNT4 content in human brain vascular smooth muscle cells stimulated by normal human serum was the lowest, with no significant difference from the group without serum stimulation; the WNT4 content in human brain vascular smooth muscle cells stimulated by the serum of patients with ischemic moyamoya disease was slightly higher than that of normal people; the WNT4 content in the serum of patients with hemorrhagic moyamoya disease was the highest, significantly higher than that of normal people and patients with ischemic moyamoya disease. Figure 2 The Control group was human cerebral vascular smooth muscle cells without serum stimulation, the HC group was human cerebral vascular smooth muscle cells stimulated with normal human serum, the IS group was human cerebral vascular smooth muscle cells stimulated with serum from patients with ischemic moyamoya disease, and the HEM group was human cerebral vascular smooth muscle cells stimulated with serum from patients with hemorrhagic moyamoya disease.
[0084] This indicates that if the WNT4 content in the serum of the test subject or in human cerebral vascular smooth muscle cells stimulated by the serum of the test subject is abnormally higher than the normal level, the test subject is very likely to suffer from hemorrhagic moyamoya disease.
[0085] Example 2: Effect of overexpression of WNT4 on cell apoptosis and migration
[0086] 1. Construction of overexpression lentiviral vector
[0087] Specific primers were designed for the full-length sequence of the CDS region of WNT4, and two restriction sites, SpeI (ACTAGT) and XbaI (TCTAGA), were added to the upstream and downstream of the primers according to the multiple cloning site of the pLVX-Puro vector, and the PCR products with double restriction sites of SpeI and XbaI were purified and recovered. The primer sequences of WNT4 are Forward: 5'-GACTAGTATGAGTCCCGCTCGTG-3'; Reverse: 5'-GCTCTAGATCATCGGCACGTGTGCAAC-3'.
[0088] According to the table below, prepare 50 μL of enzyme digestion system. Add various reagents in order, mix them by gently blowing with a pipette, centrifuge briefly, and react at 37°C for 3 hours. Perform agarose gel electrophoresis on the vector digestion products to recover the target bands.
[0089] Reagents Volume (μL) ddH2O 41 10×CutSmart Buffer2 5 Purified plasmid DNA (1 μg / μL) 2 SpeⅠ(10U / μL) 1 XbaⅠ(10U / μL) 1 Total 50
[0090] The double-digested linearized vector and annealed double-stranded DNA were connected by T4 DNAligase and ligated at 16°C overnight. The reaction system is as follows:
[0091] Reagents Volume (μL) Linearized vector (100ng / μL) 1 Double-stranded DNA (100ng / μL) 1 10×T4 DNA ligase buffer 2 T4 DNA ligase 1 ddH2O Top up to 20
[0092] Add 10 μL of reaction product to 100 μL of competent cells, gently tap the tube wall to mix, place on ice for 30 min, heat shock at 42°C for 90 s, incubate in an ice water bath for 2 min, add 500 μL LB medium, place on a shaker at 37°C for 1 h, take an appropriate amount of bacterial solution and evenly spread it on a plate containing Amp antibiotics, and invert and culture in a constant temperature incubator for 16 h.
[0093] 2. Colony PCR identification
[0094] Prepare the following reaction system, oscillate to mix, centrifuge briefly, pick up a single colony with a sterile pipette tip and put it into 20 μL of identification system in an ultra-clean workbench, mix by pipetting, and place in a PCR instrument for reaction.
[0095] Reagents Volume (μL) ddH2O 9.2 2×Taq Plus Master Mix 10 Upstream primer (10 μM) 0.4 Downstream primer (10 μM) 0.4 Single colony - Total 20
[0096] PCR reaction conditions:
[0097]
[0098] The identified positive clones were inoculated into an appropriate amount of LB liquid culture medium containing Amp antibiotics, cultured at 37°C for 16 h, and an appropriate amount of bacterial liquid was taken for sequencing.
[0099] 3. Plasmid extraction
[0100] The correctly sequenced bacterial solution was inoculated into 10mL LB liquid culture medium containing Amp antibiotics, cultured at 37℃ overnight, and the overnight cultured bacterial solution was collected into a labeled 5mL centrifuge tube, and centrifuged at 12000rpm for 2min to collect the bacteria; the supernatant was discarded, 250μL of cell resuspension solution was added, and the bacterial blocks were fully vortexed to suspend evenly; 250μL of cell lysis solution was added, and then 10μL of proteinase K was added, and the tube was inverted 5-6 times to mix gently; it was allowed to stand for 1-2min to cause the bacteria to lyse and clarify; 350μL of neutralizing solution was added, and the tube was inverted to mix so that the protein was completely precipitated, and it was allowed to stand in an ice bath for 5min; centrifuged at 10000rpm for 10min, the protein was discarded, and the supernatant was collected into another clean and sterile 1.5mL EP tube; centrifuge at 2000rpm for 5min, prepare a marked recovery column, transfer the supernatant to the recovery column, centrifuge at 12000rpm for 1min, discard the lower layer of waste liquid; add 600μL of pre-prepared rinse solution, centrifuge at 12000rpm for 1min, discard the lower layer of waste liquid, repeat once, centrifuge at 12000rpm for 2min, further remove the residual rinse solution; transfer the recovery column to a new 1.5mL EP tube in the clean bench, let it stand for 10min, and dry naturally; add 95μL Nuclease-FreeWater to the recovery column, let it stand for 2min, centrifuge at 12000rpm for 2min, collect the samples and number them, which are oe-Vector and oe-Wnt4 respectively.
[0101] 4. Lentivirus packaging
[0102] 24 h before transfection, 239T cells in the logarithmic growth phase were digested with trypsin and the cell density was adjusted to 5×10 6 cell / 15mL, re-inoculated in 10cm 2 Culture the cells in a cell culture dish at 37°C and 5% CO2 until the cell density reaches 70% to 80% and can be used for transfection.
[0103] 2 h before transfection, replace the medium with serum-free medium, prepare a sterile centrifuge tube, add 20 μg vector plasmid, 15 μg pHelper1.0 vector plasmid and 10 μg pHelper 2.0 vector plasmid, mix well with the corresponding volume of GeneCare transfection reagent, adjust the total volume to 1 mL, and incubate at room temperature for 15 min.
[0104] Slowly add the mixture to the 293T cell culture medium, mix well, and culture at 37°C, 5% CO2. After 6 hours of culture, discard the culture medium containing the transfection mixture, add 10mL PBS solution to wash once, gently shake the culture dish to wash the residual transfection mixture and then discard it. Slowly add 20mL of cell culture medium containing 10% serum, and culture at 37°C, 5% CO2 for 48 hours.
[0105] Collect the supernatant of 293T cells 48 hours after transfection, centrifuge at 4000g for 10 minutes at 4°C to remove cell debris. Add the supernatant to a 40mL ultracentrifuge tube with a 0.45μm filter, and centrifuge at 25000rpm at 4°C for 2 hours. After centrifugation, discard the supernatant, try to remove the liquid remaining on the tube wall, add the virus preservation solution, and gently pipette repeatedly.
[0106] After fully dissolved, centrifuge at 10,000 rpm for 5 min and take the supernatant.
[0107] 5. Lentivirus titer detection
[0108] One day before the assay, 293T adherent cells were plated in 96-well plates with 4 × 10 4 cells, 100 μL volume, prepare 10 sterile EP tubes, add 90 μL serum-free medium to each tube, take 10 μL of the virus stock solution to be tested and add it to the first tube, mix well, take 10 μL and add it to the second tube, continue the same operation until the last tube. Discard 90 μL of medium in the cell plate, add 90 μL of diluted virus solution, and culture at 37°C, 5% CO2. After 24 hours, add 100 μL of complete medium, and detect the virus titer by RT-PCR 4 days later.
[0109] 6. Lentiviral transfection
[0110] 24 h before transfection, 0.5 × 10 5 HBVSMC cells were cultured overnight in an incubator at 37°C and a CO2 concentration of 5%. The serum-free culture medium and Polybrene were mixed to a final concentration of 5μg / mL. The culture medium in the 24-well plate was replaced with 0.5mL of the Polybrene-culture medium mixture per well. According to the MOI value, the corresponding volume of lentivirus was added to each well. After incubation overnight, the culture medium was removed and 1mL of complete culture medium was added to each culture well. The culture was continued at 37°C and a CO2 concentration of 5% in an incubator. After the cells were fully grown, the cells were passaged at a ratio of 1:3. After 48 hours of culture, the cell culture medium in the culture dish was replaced with a 2μg / mL Puromycin selection culture medium and the culture was continued. After the cells can stably amplify in the Puromycin selection culture medium, the transfection efficiency was verified using a PCR experiment. The results are as follows: Figure 3 As shown, the Control group is HBVSMC cells without transfection, the oe-Vector group is HBVSMC cells transfected with an empty vector, and the oe-Wnt4 group is HBVSMC cells transfected with an overexpressing WNT4 vector. Compared with HBVSMC cells without transfection and transfected with an empty vector, the expression of WNT4 in HBVSMC cells transfected with an overexpressing WNT4 vector was significantly increased, indicating that the oe-Wnt4 group was successfully transfected.
[0111] After the HBVSMC cells were treated accordingly, they were rinsed twice with PBS; the cells were treated with EDTA-free trypsin, and when the cells were deformed and the cell-to-cell connections disappeared, the digestion was terminated with complete culture medium; the cell suspension was transferred to a sterile centrifuge tube, centrifuged at 800 rpm for 5 min, and the supernatant was discarded; 0.5 mL of staining buffer was added to resuspend the cells; 5 μL of FITC stain and 5 μL of PI stain were added, gently pipetted and mixed, and incubated in the dark for 15 min at room temperature; and detected by flow cytometer.
[0112] Use a UV-sterilized marker pen to draw horizontal lines evenly on the back of the 6-well plate, approximately every 0.5-1 cm, across the holes, and draw at least 5 lines in each hole. Digest the cells in the logarithmic growth phase with trypsin to form a single cell suspension, add appropriate culture medium to adjust the concentration of the cell suspension, and seed 2 mL of a 6×10 5 / mL of cells to ensure that the cells can grow full the next day, and the final total amount of culture medium in each well is 2mL. Culture in a 37℃, 5% CO2 cell culture incubator according to the grouping requirements. After 24 hours, observe under a microscope that the cells are attached to the wall and evenly distributed. In the clean bench, use a disinfected 200μL gun tip to scratch perpendicular to the marked horizontal line on the back. The gun tip should be vertical and not tilted. Wash the cells three times with PBS, remove the scratched cells, add serum-free culture medium, and culture in a 37℃, 5% CO2 incubator. Take pictures at 100× to ensure that the scratch is centered and vertical, pay attention to the consistency of the background, take samples according to the time point, and take pictures and record.
[0113] The results are as follows Figure 4 As shown, in Figure 4 In AD, oe-Vector was the control group transfected with an empty vector, and oe-Wnt4 was the experimental group overexpressing WNT4.
[0114] Figure 4 A and Figure 4 B is the comparison of cell apoptosis detection between the two groups. Figure 4 A and Figure 4 B shows that the cell apoptosis in the WNT4 overexpression group (16.32%) was significantly higher than that in the control group (7.61%). This indicates that overexpression of WNT4 can increase the apoptosis of vascular cells in moyamoya disease, leading to damage at the cellular level.
[0115] Figure 4 C and Figure 4 D is the comparison of scratch test results of the two groups. Figure 4 C and Figure 4 D shows that at 0h, the width of the scratches in the WNT4 overexpression group and the control group was the same; at 24h, the width of the scratches in both the WNT4 overexpression group and the control group was significantly narrowed, but the narrowing degree in the WNT4 overexpression group was significantly lower than that in the control group. This indicates that overexpression of WNT4 can reduce the migration ability of vascular cells in moyamoya disease, leading to damage at the cellular level.
[0116] Normal apoptosis and migration of smooth muscle cells are key to maintaining normal vascular structure. Increased apoptosis of vascular cells is closely related to repeated hemorrhagic stroke in hemorrhagic moyamoya disease. Abnormal migration of vascular smooth muscle cells is one of the important mechanisms leading to vascular stenosis. Therefore, the apoptosis and migration abnormalities caused by overexpression of WNT4 are consistent with the pathological manifestations of hemorrhagic moyamoya disease, proving that WNT4 is a biomarker for hemorrhagic moyamoya disease.
[0117] Example 3: Exploration of WNT4-related pathways in hemorrhagic moyamoya disease
[0118] The transfected HBVSMC cells obtained according to the method of Example 2 were used to detect the expression levels of Wnt4, GSK3β, p-GSK3β, Tau, β-catenin, active-β-catenin, p-Tau, PSEN1, TUBA, and TUBB in each group by Western Blot method (refer to Example 1) (GAPDH was used as an internal reference).
[0119] The results are as follows Figure 5 As shown, in Figure 5 In AK, oe-Vector was the control group transfected with an empty vector, and oe-Wnt4 was the experimental group overexpressing WNT4.
[0120] Figure 5 A is the Western Blot results of the two groups. Figure 5 BK is a bar graph of cytokine expression. Figure 5 AK showed that compared with the control group, there was no significant difference in the expression levels of GSK3β and Tau in the experimental group overexpressing WNT4, the expression levels of Wnt4, β-catenin, active-β-catenin, PSEN1, TUBA, TUBB and the phosphorylation level of Tau were significantly increased, and the phosphorylation level of GSK3β was significantly decreased.
[0121] The experimental results showed that the WNT4 expression level of HBVSMC transfected with overexpression lentiviral plasmid was significantly higher than that of control HBVSMC transfected with empty plasmid, indicating successful transfection. In addition, GSK3β and β-catenin are key molecules in the WNT / β-catenin signaling pathway, and Tau, PSEN1, TUBA, and TUBB are downstream molecules of the signaling pathway. Overexpression of WNT4 causes increased expression levels of β-catenin and activeβ-catenin, decreased phosphorylation levels of GSK3β, activated the WNT / β-catenin signaling pathway, and continued to affect downstream molecular pathways, leading to increased expression levels of PSEN1, TUBA, and TUBB; although it did not affect the expression level of Tau, it increased the phosphorylation level of Tau. Tau is a microtubule-associated protein that has a role in cellular microtubule stability. Excessive phosphorylation will cause the loss of Tau's microtubule stabilization function, thereby causing dysfunction of cell microtubules and cytoskeleton, and ultimately leading to cell damage. TUBA and TUBB are tubulins α and β, which are components of cell microtubules. Increased expression of TUBA and TUBB indicates an abnormal state of cells. Therefore, overexpression of WNT4 leads to decreased stability of cell microtubules, which is consistent with the hemorrhagic stroke that often occurs in hemorrhagic moyamoya disease, proving that WNT4 is a biomarker for hemorrhagic moyamoya disease.
[0122] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and changes may be made to the details according to all the teachings that have been published, and these changes are within the scope of protection of the present invention. The entire invention is given by the attached claims and any equivalents thereof.
Claims
1. A biomarker for diagnosing hemorrhagic moyamoya disease, characterized in that: The biomarker is WNT4 (Wingless-type MMTV integration site family member 4).
2. The biomarker according to claim 1, characterized in that The amino acid sequence of the biomarker is shown in SEQ ID No.
1.
3. Use of the biomarker according to any one of claims 1 to 2 in the preparation of a detection reagent or a detection kit for hemorrhagic moyamoya disease.
4. Use of a reagent for detecting the biomarker according to any one of claims 1 to 2 in a biological sample in the preparation of a detection reagent or a detection kit for hemorrhagic moyamoya disease.
5. The use according to claim 4, characterized in that: The biological sample is derived from the blood or serum of the subject to be tested.
6. The use according to claim 4, characterized in that: The biological sample is obtained by the following steps: (1) Human cerebral vascular smooth muscle cells were incubated in cell culture medium containing 2% FBS for 24 hours; (2) stimulating the human brain vascular smooth muscle cells obtained in step (1) with a serum stimulation medium, wherein the serum stimulation medium contains 2.5% heat-inactivated serum of the subject to be tested; (3) The biological sample is derived from human cerebral vascular smooth muscle cells or a culture / extract thereof obtained in step (2).
7. The use according to claim 4, characterized in that: The reagents include reagents for detecting the biomarker at the protein level.
8. The use according to claim 4, characterized in that: The method for detecting the biomarker as claimed in claim 1 in a biological sample comprises ELISA and / or Western Blot.
9. A detection reagent or detection kit for hemorrhagic moyamoya disease, comprising a reagent for detecting the biomarker according to any one of claims 1 to 2 in a biological sample.
10. Use of the biomarker according to any one of claims 1 to 2 as a target in the preparation of a drug for treating hemorrhagic moyamoya disease.
